|
Mechanismβ2-adrenergic receptor agonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismmAChRs antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 3 EXPLORATIVE, RANDOMIZED, PLACEBO CONTROLLED STUDY FOR THE CLINICAL EVALUATION OF PIDOTIMOD IN FEMALE PATIENTS WITH RECURRENT, UNCOMPLICATED URINARY TRACT INFECTIONS.
/ Not yet recruitingPhase 3 Combined treatment with pidotimod and bifidobacteria in pre-scholastic age children with recurrent respiratory infections: evaluation of clinical efficacy and parents' quality of life - MB0515/1021/03
/ Not yet recruitingNot Applicable Effects of Treatment with Cefaclor in acute pharyngotonsillitis and activity on the immune system - Cefaclor - Activity on the immune system
100 Clinical Results associated with Valeas SpA Industria Chimica E Farmaceutica
0 Patents (Medical) associated with Valeas SpA Industria Chimica E Farmaceutica
100 Deals associated with Valeas SpA Industria Chimica E Farmaceutica
100 Translational Medicine associated with Valeas SpA Industria Chimica E Farmaceutica